In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Moody's Ratings (Moody's) affirmed the ratings of CVS Health Corporation ("CVS") including the Baa2 senior unsecured notes, (P)Baa2 senior unsecured shelf and Prime-2 senior unsecured commercial paper rating. At the same time, we revised CVS's outlook to negative from stable. The affirmation of th...
EQS-News: DocCheck AG / Schlagwort(e): Sonstiges Alles auf Rot - Aus „antwerpes“ wird 'DocCheck Agency“ 17.07.2024 / 10:38 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Die DocCheck AG plant die Umbenennung der antwerpes Agenturgruppe. Sie soll zum 4. Quartal 2024 erfolgen. „Wir werden im Healthcare-Markt künftig nur noch mit einer Marke auftreten. Und die ist rot.“ so Dr. Frank Antwerpes, CEO der DocCheck AG. Die Agenturgruppe bleibt unter der neuen Firmierung als eigenständige Einheit bestehen. Parallel zur Umbenennung wird die k...
Moody's Ratings (Moody's) assigned a Baa2 rating to the new senior unsecured notes issuance of CVS Health Corporation ("CVS"). There are no changes to CVS's existing ratings including the Baa2 senior unsecured long-term rating or the Prime-2 commercial paper rating. The outlook remains unchanged at ...
Two Directors at CVS Health Corp bought 10,181 shares at between 53.879USD and 54.492USD. The significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
EQS-News: DocCheck AG / Schlagwort(e): Quartalsergebnis Vorläufige Zahlen zum ersten Quartal 2024 02.05.2024 / 18:29 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Die DocCheck Gruppe (ISIN DE000A1A6WE6) gibt heute vorläufige Zahlen für das erste Quartal 2024 bekannt. Die Umsatzerlöse der ersten drei Monate 2024 betragen 12,1 Millionen Euro (Vorjahr: 13,7 Millionen Euro). Der daraus erzielte EBIT liegt bei 1,0 bis 1,1 Millionen Euro (Vorjahr: 1,2 Millionen Euro). Die rückläufige Umsatz- und Ergebnisentwicklung resultiert aus einem s...
Moody's Ratings ("Moody's") commented on CVS Health Corporation's (Baa2 stable) continuing pressure in its Medicare Advantage business, which prompted a significant downward revision in 2024 earnings guidance. These events are credit negative because of the impact on CVS's financial leverage, with g...
Moody's Investors Service ("Moody's") affirmed the ratings of CVS Health Corporation ("CVS") including the Baa2 senior unsecured notes ratings, the Prime-2 senior unsecured commercial paper rating and the (P)Baa2 senior unsecured shelf rating. The outlook is maintained stable. The affirmation foll...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.